Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
688222.SS
HOLDREMOVEHitGen Inc. · Healthcare · China · $1.8B · Avg Vol: $82M/d
HitGen is a drug discovery platform utilizing DNA-encoded chemical libraries. While technically advanced, it does not possess the commercial scale, recurring revenue, or pricing power of a validated CDMO, failing our CDMO Pricing Power theme.
COMPANY DESCRIPTION
HitGen is a biotechnology company specializing in early-stage drug discovery, utilizing its proprietary DNA-encoded chemical library (DEL) platform. The company's moat is built on its massive, diverse library of billions of small molecules, which serves as a critical resource for global pharmaceutical partners. HitGen is recognized as a global leader in DEL technology, offering both platform access and co-development services.
FINANCIAL SUMMARY
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 49M | 55M | 63M | 78M | 16.8% |
| EPS | 0.01 | 0.01 | 0.02 | 0.04 | 65.1% |
| Shares | 401M | 401M | 401M | 401M | 0.0% |
| Debt | 36M | 34M | 32M | 35M | -0.9% |
| Equity | 193M | 201M | 206M | 222M | 4.8% |
| Op CF | 8M | 19M | 19M | 32M | 60.1% |
| Inv CF | -2M | -12M | -754,327 | -6M | — |
| Fin CF | -7M | -4M | -6M | -1M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688222.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 688222.SS | HitGen Inc.(you) | $1.8B | 47 | HOLD |
| 301207.SZ | Hualan Biological Vaccine Inc. | $1.6B | 47 | HOLD |
| 600201.SS | Jinyu Bio-technology Co., Ltd. | $1.9B | 48 | HOLD |
| 688319.SS | Chengdu Olymvax Biopharmaceuticals Inc. | $2.1B | 45 | HOLD |
| 300049.SZ | Inner Mongolia Furui Medical Science Co., Ltd. | $1.7B | 40 | HOLD |
| 600866.SS | Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | $1.2B | 46 | HOLD |
| 9969.HK | InnoCare Pharma Limited | $2.6B | 48 | HOLD |
| 688366.SS | Shanghai Haohai Biological Technology Co., Ltd. | $1.1B | 48 | HOLD |
| 688739.SS | Liaoning Chengda Biotechnology Co.,Ltd. | $1.3B | 42 | HOLD |
| 301301.SZ | Yili Chuanning Biotechnology Co.,Ltd. | $2.9B | 46 | HOLD |
Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 53.0%